Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.73 |
| ▸ | CTSK | P43235 | 5/20 | 0.73 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955720 | 1.00 | CTSS (0.73) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL1068894 | 1.00 | CTSS (0.73) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL16460386 | 0.85 | CTSS (0.64) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL16460387 | 0.85 | CTSS (0.64) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL10094308 | 0.83 | CTSS (0.62) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL18084174 | 0.83 | CTSS (0.62) | CTSSCTSKACEPPARAPPARG | |
| SCHEMBL3573493 | 0.83 | CTSS (0.52) | CTSSCTSKITGB3FOLH1 | |
| SCHEMBL11022657 | 0.83 | CTSS (0.61) | CTSSCTSKACECTSLCTSB | |
| SCHEMBL16119123 | 0.80 | FOLH1 (0.49) | CTSSCTSKFOLH1 | |
| SCHEMBL8308836 | 0.80 | CTSS (0.70) | CTSSCTSKACECTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655322-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | Diverchim (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085474-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | DIVERCHIM (FR) | 2012-06-28 | — | — | WO | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| US-4338434-A | ANTIBIOTICS AND ANIMAL FEED SUPPLEMENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-07-06 | — | — | US | disclosed |
| US-4215118-A | BACTERICIDES, ANIMAL GROWTH PROMOTERS, PRESERVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | CTSS 1598/4885CTSK 365/4885ACE 848/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885ACE 1332/4885 |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CTSS 843/4885CTSK 100/4885ACE 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.